John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Molecular aspects and perspectives in pancreatic cancer: evolutions and revolutions? Volume 24, supplement 2, Juin 2017

Figures

  • Figure 1

Tables

Authors
1 Université Paris 7 - Denis Diderot, Hôpital Beaujon,
INSERM UMR1149,
100 boulevard du Général Leclerc,
92110 Clichy-La-Garenne,
France
2 Hôpital Henri-Mondor,
service d’oncologie médicale,
51 avenue du Maréchal de Lattre de Tassigny,
94010 Créteil,
France
3 Groupe Hospitalier Pitié-Salpêtrière,
Sorbonne Université-Paris 6 – Université Pierre et Marie Curie, service d’hépato-gastro-entérologie,
47-83 Boulevard de l’hôpital,
75651 Paris Cedex 13,
France
* Tirés à part

Therapeutic options for advanced pancreatic ductal adenocarcinoma (PDAC) are limited. Gemcitabine has been the standard chemotherapy until 2011, when the FOLFIRINOX regimen (combining 5-FU, irinotecan, and oxaliplatine) and then the gemcitabine plus nab-paclitaxel regimen demonstrated a survival benefit over gemcitabine alone in metastatic PDAC. Despite these significant achievements, new therapeutic options and strategies for advanced PDAC are crucially needed. Most of the « targeted » therapies that have shown efficacy in other cancer types did not yield significant survival benefit in advanced PDAC patients. A better understanding of the molecular mechanisms of pancreatic carcinogenesis, as well as its microenvironment has led to the development of new concepts and innovant therapeutic strategies. The aim of this review is to provide an overview of these recent evolutions (and revolutions?) in PDAC therapy.